Commentary

Article

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

Speakers

  • Adrienne Waks, MD | Dana-Farber Cancer Institute
  • Sarah Sammons, MD | Dana-Farber Cancer Institute
  • Erica Mayer, MD, MPH | Dana-Farber Cancer Institute
  • Filipa Lynce, MD | Dana-Farber Cancer Institute
  • Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute

Topics

  • Tailoring Treatment for HER2+ Early and Metastatic Breast Cancer
  • The Expanding Arsenal for Treating HR+/HER2- Metastatic Breast Cancer: CDK4/6i, PI3K/AKTi, SERDs and Beyond
  • Treatment of the Endocrine-Refractory Disease: Moving Beyond Traditional Chemotherapy
  • Evolving Trends in the (Neo)adjuvant Systemic Treatment of HR+/ HER2- Breast Cancer
  • Triple-Negative Breast Cancer: Targeting the Once Targetless Subtype
  • Targeting DNA Damage Response Pathways in Breast Cancer: Current Status, Opportunities and Pitfalls
  • On the Horizon: Novel Targets and Therapeutic Strategies in Breast Oncology

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Andrew Davis, MD
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Video 5 - 2 KOLs are featured in, "Targeted Therapies in HR+/HER2- mBC: CAPItello-291"
2 KOLs are featured in this program.
2 KOLs are featured in this program.
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"